Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.09.28.559941

NEW INSIGHTS INTO THE HEPATIC IRON PHENOTYPE OF BMP6 KNOCKOUT MICE

Abstract

ObjectiveBmp6 knockout (KO) mice progressively accumulate a significant amount of iron in their liver as they age due to a defect in hepcidin (Hamp) expression and an upregulation of the iron exporter ferroportin (Fpn). In this study, we conducted a comprehensive investigation of the hepatic iron overload phenotype, with specific emphasis on the cellular and subcellular localization of Fpn in Bmp6 KO mice. Materials and MethodsLivers obtained from Bmp6 knockout (KO) mice at different developmental stages were utilized for the quantification of iron content, investigation of iron distribution, histological analysis, histoimmunofluorescence assays performed on paraffin-embedded sections, confocal microscopy examinations, subcellular membrane fractionation, and western blot analysis. ResultsIn Bmp6 KO livers, iron overload increased with age and was not homogeneous, with certain hepatic lobes and specific areas in liver sections showing more pronounced iron accumulation. In young mice, iron accumulated mostly in the centrilobular zone where low Fpn expression was observed. Fpn was strongly detected in periportal Kupffer cells and at the apical membrane of periportal hepatocytes lining the sinusoidal capillaries. The zonal distribution of iron tended to disappear with age in strongly iron-overloaded areas, with the appearance of large cellular aggregates strongly positive for Fpn, iron, and ceroid/lipofuscin. At the subcellular level, hepatic Fpn seemed to concentrate in specific cell surface compartments and was enriched in a lipid raft fraction. ConclusionsUnregulated expression of Fpn on the cell surface of periportal macrophages and hepatocytes results in centrilobular iron overload within hepatocytes. In areas of pronounced iron overload, Fpn expression is present in lipogranulomas, identified as aggregations of macrophages accumulating hemosiderin and ceroid/lipofuscin pigments. These lesions likely form due to the phagocytosis of sideronecrotic/ferroptotic hepatocytes by macrophages. In contrast to the duodenal form of Fpn, both splenic and hepatic Fpn demonstrated robust enrichment within lipid rafts. The observed variations in the subcellular localization of Fpn could play a significant role in influencing the transporters iron transport activity and/or its regulation by hepcidin.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

BESSON, C., WILLEMETZ, A., LATOUR, C., ROBERT, L., COPPIN, H., ROTH, M.-P., CANONNE-HERGAUX, F.. 2023-09-29. NEW INSIGHTS INTO THE HEPATIC IRON PHENOTYPE OF BMP6 KNOCKOUT MICE. https://doi.org/10.1101/2023.09.28.559941

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗

TREM2-stimulated, PDGF-dependent macrophage-fibroblast crosstalk induces beneficial plaque remodeling in clonal hematopoiesis

Background: In Jak2V617F clonal hematopoiesis, inflammatory signaling suppresses macrophage TREM2 and promotes features of plaque instability, while therapeutic TREM2 agonism reverses plaque instability by increasing fibroblasts and fibrous cap formation. We tested whether macrophage-derived PDGFB and stromal cell PDGFR? signaling mediate this response. Methods: Low allele burden (LAB) Jak2V617F atherosclerosis models were combined with inducible Pdgfb deletion in CX3CR1-lineage monocytes/macrophages or Pdgfra deletion in Col1a2-lineage fibroblast-enriched stromal cells. Mice were treated with the TREM2 agonist 4D9. Plaque composition, macrophage-fibroblast interactions, and aortic stromal cell populations were analyzed. Human WT and JAK2V617F iPSC-derived macrophages were used for validation. Results: TREM2 activation with 4D9 increased macrophage PDGFB production and promoted fibrous cap formation in LAB Jak2V617F atherosclerosis. Deletion of Pdgfb in CX3CR1-lineage cells markedly attenuated the 4D9-mediated increase in fibrous cap area and lesional PDGFR?+ cells, establishing macrophage-derived PDGFB as a key signal for the stromal response. Consistently, Col1a2-lineage Pdgfra deletion abolished the 4D9-induced fibrous cap response without significantly altering lesion or necrotic core area. Single cell RNA-seq identified increased Fmod+ and CD26/Dpp4+ fibroblast populations associated with 4D9 treatment. Fmod+ fibroblasts represented an abundant matrix-associated population, whereas CD26+ fibroblasts showed greatest enrichment, prominent extracellular matrix, collagen organization, and matrix-remodeling programs that were enhanced by 4D9 and attenuated by Pdgfra deletion. The stromal response was also associated with reduced macrophage migration-related programs and predicted chemokine communication from CD26+ fibroblasts to macrophages which was verified by macrophage migration studies. Moreover, stromal Pdgfra deletion increased lesional CCR2+ and CCR5+ macrophages. Conclusions: In a CH model of inflammatory atherosclerosis, TREM2 activation promotes a macrophage PDGFB-stromal PDGFR? pathway that expands Fmod+ and CD26+ fibroblast populations and increases fibrous cap matrix formation. CD26+ fibroblasts impair macrophage chemotaxis in a DPP4-dependent manner, suggesting reciprocal macrophage-fibroblast communication that coordinates matrix remodeling and inflammatory cell trafficking in the plaque.

pathology↗